phenobarbital sodium msds - An Overview
phenobarbital sodium msds - An Overview
Blog Article
pentobarbital will lower the level or effect of etravirine by affecting hepatic enzyme CYP2C9/ten metabolism. Use Caution/Check.
pentobarbital will lower the extent or effect of zolpidem by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unidentified.
pentobarbital will lower the level or effect of theophylline by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
Administer barbiturates with caution in people with hepatic injury and at lessened doses at first; barbiturates shouldn't be administered to individuals demonstrating the premonitory indications of hepatic coma
Keep track of Closely (1)pentobarbital will decrease the extent or effect of mestranol by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will minimize the extent or effect of roflumilast by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration not encouraged; sturdy cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and should lessen the therapeutic effectiveness
pentobarbital will minimize the extent or effect of methadone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
pentobarbital will decrease the level or effect of parecoxib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Unfamiliar.
pentobarbital will reduce the extent or effect of itraconazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unidentified.
Estradiol, estrone, progesterone and other steroidal hormones: Pretreatment with or concurrent administration of phenobarbital may lower the effect of estradiol by increasing its metabolism.
Keep track of Closely (one)pentobarbital will lower the level or effect of gefitinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
Observe Closely (1)pentobarbital will minimize the extent or effect of osilodrostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital and olopatadine intranasal both enhance sedation. Keep away from or Use Alternate Drug. Coadministration improves chance of CNS depression, which may lead to additive impairment of psychomotor efficiency and induce daytime impairment.
pentobarbital will minimize the extent or effect of fruquintinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. website If coadministration with reasonable CYP3A4 inducers is unavoidable, go on to administer fruquintinib at recommended dosage.